Hinge Health (NYSE:HNGE) Price Target Raised to $80.00 at Wells Fargo & Company

Key Points

• Wells Fargo raised its price target on Hinge Health to $80 from $68 and maintains an "overweight" rating, implying roughly a 46% upside from the prior close.
• Hinge reported a Q1 beat with $0.45 EPS vs. $0.12 expected and revenue of $182.3M (up 47% YoY), and management raised FY2026 revenue guidance to $798–$804M while launching an FDA-cleared Enso migraine program that expands the business beyond MSK.
• Insiders have been net sellers recently: the CEO and CFO disclosed large sales and insiders sold 442,670 shares (~$18.8M) over the last three months, though insiders still own about 18.9% of the company.

Hinge Health (NYSE:HNGE - Get Free Report) had its target price hoisted by investment analysts at Wells Fargo & Company from $68.00 to $80.00 in a report released on Wednesday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price target suggests a potential upside of 46.33% from the stock's previous close.

HNGE has been the topic of a number of other research reports. Canaccord Genuity Group decreased their target price on shares of Hinge Health from $65.00 to $53.00 and set a "buy" rating on the stock in a research report on Wednesday, February 11th. KeyCorp set a $55.00 target price on shares of Hinge Health in a research report on Wednesday, February 11th. Citigroup reiterated an "outperform" rating on shares of Hinge Health in a research note on Wednesday. Piper Sandler cut their price target on shares of Hinge Health from $71.00 to $60.00 and set an "overweight" rating on the stock in a research note on Friday, January 9th. Finally, Needham & Company LLC boosted their price target on shares of Hinge Health from $59.00 to $63.00 and gave the stock a "buy" rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $59.13.

Hinge Health Trading Up 9.9%

NYSE HNGE traded up $4.92 during trading hours on Wednesday, reaching $54.67. The company had a trading volume of 1,368,442 shares, compared to its average volume of 1,173,944. The stock has a 50-day moving average of $42.20 and a 200 day moving average of $43.94. Hinge Health has a 1-year low of $30.08 and a 1-year high of $62.18. The stock has a market capitalization of $4.31 billion and a P/E ratio of -4.24.

Hinge Health (NYSE:HNGE - Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.33. The company had revenue of $182.31 million during the quarter. During the same quarter in the prior year, the firm earned $1.30 earnings per share. Hinge Health's revenue was up 47.2% compared to the same quarter last year. As a group, sell-side analysts predict that Hinge Health will post 0.78 EPS for the current year.

Insider Activity

In related news, CFO James Budge sold 11,006 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $42.26, for a total transaction of $465,113.56. Following the sale, the chief financial officer directly owned 401,427 shares in the company, valued at approximately $16,964,305.02. This represents a 2.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Antonio Perez sold 166,665 shares of the company's stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $40.26, for a total transaction of $6,709,932.90. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 442,670 shares of company stock valued at $18,786,901 over the last three months. 18.92% of the stock is currently owned by corporate insiders.

Institutional Trading of Hinge Health

A number of large investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC increased its stake in shares of Hinge Health by 3.3% during the first quarter. Janney Montgomery Scott LLC now owns 9,400 shares of the company's stock worth $362,000 after buying an additional 300 shares during the period. Wells Fargo & Company MN increased its stake in shares of Hinge Health by 160.0% during the fourth quarter. Wells Fargo & Company MN now owns 546 shares of the company's stock worth $25,000 after buying an additional 336 shares during the period. First Horizon Corp increased its stake in shares of Hinge Health by 163.9% during the fourth quarter. First Horizon Corp now owns 855 shares of the company's stock worth $40,000 after buying an additional 531 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Hinge Health in the fourth quarter valued at approximately $26,000. Finally, Sandler Capital Management boosted its holdings in Hinge Health by 1.4% in the third quarter. Sandler Capital Management now owns 52,728 shares of the company's stock valued at $2,588,000 after purchasing an additional 728 shares in the last quarter.

Key Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q1 beat — Hinge reported $0.45 EPS vs. $0.12 expected and revenue of $182.3M, up 47% year-over-year, showing solid demand and execution. Hinge Health reports record first quarter 2026 financial results
• Positive Sentiment: Raised guidance — management lifted FY2026 revenue guidance to $798M–$804M (consensus ~$741M) and gave Q2 revenue guidance of $194M–$196M, both above Street expectations, implying continued top-line acceleration. Hinge Health forecasts $798M-$804M 2026 revenue while launching FDA-cleared Enso migraine program
• Positive Sentiment: New product expansion — Hinge launched an FDA-cleared Enso migraine program, extending the platform beyond MSK into a large, recurring-condition market that can lift LTV and average revenue per member. Hinge Health forecasts $798M-$804M 2026 revenue while launching FDA-cleared Enso migraine program
• Neutral Sentiment: Management tone / strategy — the earnings call emphasized automation, unit economics improvement and a “long runway” for expansion; useful for investors modeling margins but not an immediate catalyst. Hinge Health, Inc. (HNGE) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Technical interest — RSI/RS rating and pre-earnings momentum were noted by some outlets, which can amplify intraday moves but is not fundamental. Hinge Health stock sees RS rating jump ahead of earnings
• Negative Sentiment: Profitability mixed — while quarterly EPS beat estimates, EPS is lower versus the prior-year quarter ($1.30 to $0.45), highlighting variability and potential one-offs; investors should probe drivers in the call deck. Hinge Health Q1 earnings summary
• Negative Sentiment: Valuation / profitability risk — Hinge still shows a negative P/E and is priced for growth; if revenue acceleration slows or margins don’t improve, the stock could re-rate. HNGE stock profile

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.